Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 99-104

  Subramanian, Sreedhar ^a   Yajnik, Vijay ^b   Sands, Bruce E ^b   Cullen, Garret ^b   Korzenik, Joshua R ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

anti TNF therapy; drug induced lupus erythematosus; inflammatory bowel diseases; infliximab

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; HISTONE ANTIBODY; INFLIXIMAB;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEAR; FEMALE; HEMATURIA; HUMAN; INFLAMMATION; KIDNEY FUNCTION TEST; LUPUS LIKE SYNDROME; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RETREATMENT; SEX RATIO; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; COHORT STUDIES; DNA; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650110438     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21370     Document Type: Article

References (28)

1. Ramos-Casals M, Brito-Zeron P, Soto MJ, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008; 22: 847-861.
2. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005; 7: R545-551.
3. van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, et al. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford). 2006; 45: 1317-1319.
4. Murphy SN, Chueh HC,. A security architecture for query tools used to access large biomedical databases. Proc AMIA Symp. 2002; 552-556.
5. Costa MF, Said NR, Zimmermann B,. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008; 37: 381-387.
6. Orchard TR, Wordsworth BP, Jewell DP,. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998; 42: 387-391.
7. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003; 98: 1315-1324.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
9. Buhner D, Grant JA,. Serum sickness. Dermatol Clin. 1985; 3: 107-117.
10. Roujeau JC, Stern RS,. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994; 331: 1272-1285.
11. Anderson JA,. Allergic reactions to drugs and biological agents. JAMA. 1992; 268: 2844-2857.
12. D'Arcy CA, Mannik M,. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001; 44: 1717-1718.
13. Hanauer SB, Rutgeerts PJ, D'Haens G, et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment. Gastroenterology. 1999; 116: A731.
14. Nancey S, Blanvillain E, Parmentier B, et al. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis. 2005; 11: 986-991.
15. Vedove CD, Del Giglio M, Schena D, et al. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009; 301: 99-105.
16. Garcia-Planella E, Domenech E, Esteve-Comas M, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol. 2003; 15: 351-354.
17. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003; 125: 32-39.
18. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239. (Pubitemid 47300424)
19. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238.
20. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250. (Pubitemid 47080388)
21. Colombel JF, Sandborn WJ, Reinisch W, et al. Adalimumab safety in Crohn's disease trials. Gastroenterology. 2007; 132: A-504.
22. Available at Accessed December 2, 2009.
23. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008; 117: 244-279.
24. Chaudhary R, Butler M, Playford RJ, et al. Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumamb at 10 micrograms per ml concentration. Gastroenterology. 2006; 130: A696.
25. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007; 13: 1323-1332.
26. Kocharla L, Mongey AB,. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus. 2009; 18: 169-171.
27. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004; 10: 333-338.
28. Manosa M, Domenech E, Marin L, et al. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab. Gut. 2008; 57: 559; author reply 559-560.